Clinical performance comparison of two medium cut‐off dialyzers.

Autor: Krieter, Detlef H., Rüth, Marieke, Lemke, Horst‐Dieter, Wanner, Christoph
Předmět:
Zdroj: Therapeutic Apheresis & Dialysis; Apr2023, Vol. 27 Issue 2, p284-292, 9p
Abstrakt: Introduction: Medium‐cut‐off (MCO) dialyzers may beneficially impact outcomes in patients on hemodialysis. Methods: In a randomized, controlled trial in maintenance hemodialysis patients, the new Nipro ELISIO‐17HX MCO dialyzer was compared to the Baxter Theranova 400 filter regarding middle molecule removal. Furthermore, the suitability of two assays for free lambda‐light chain (λFLC) detection (Freelite vs. N‐Latex) was verified. Results: ELISIO‐HX achieved slightly lower reduction ratios for β2‐microglobulin (71.8 ± 6.0 vs. 75.3 ± 5.8%; p = 0.001), myoglobin (54.7 ± 8.6 vs. 64.9 ± 8.7%; p < 0.001), and kappa‐FLC (62.1 ± 8.8 vs. 56.3 ± 7.7%; p = 0.021). λFLC reduction ratios were more conclusive with the Freelite assay and not different between ELISIO‐HX and Theranova (28.4 ± 3.9 vs. 38.7 ± 13.4%; p = 0.069). The albumin loss of Theranova was considerably higher (2.14 ± 0.45 vs. 0.77 ± 0.25 g; p = 0.001) and the Global Removal ScoreLoss alb largely inferior (30.6 ± 7.4 vs. 82.4 ± 29.2%/g; p = 0.006) to ELISIO‐HX. Conclusions: The new ELISIO‐HX expands the choice of dialyzers for MCO hemodialysis. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
načítá se...